Recent Finacing
Recent Raise
Monument Therapeutics develops MT1988, a fixed‑dose nicotinic receptor combination for cognitive impairment in schizophrenia, paired with proprietary digital biomarkers and cognitive assessments to stratify patients for clinical trials.
